CURE250117P97000
- 7.12
- 0.000.00%
Direxion Daily Healthcare Bull 3X Shares Newsroom
Unpacking the Latest Options Trading Trends in UnitedHealth Group
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
2024's 'Biggest Loses' That Could See Reversal in 2025
Thermo Fisher Scientific Analyst Ratings
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
Direxion Daily Healthcare Bull 3X Shares To Go Ex-Dividend On December 23rd, 2024 With 0.116 USD Dividend Per Share
Pfizer Gets FDA Accelerated Approval for Braftovi
Government Shutdown Threat: Stocks Wobble, Holiday Travel And Paychecks Could Face Delays: What You Need To Know
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
J.P. Morgan's Top Healthcare Stocks for 2025
Merck Downgraded by BMO Over Keytruda Concerns
RxSight Cut to Hold at Stifel on Competition Concerns